BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery PipelineVANCOUVER, BC / ACCESS Newswire / August 4, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to provide a comprehensive update on the progress of its proprietary sublingual thin-film drug delivery pipeline. The Company continues to advance multiple pharmaceutical development programs, including Cladribine for multiple sclerosis, autoimmune disease expansion, Everolimus and Semaglutide, while strengthening the intellectual property portfolio supporting its platform and preparing for the next phase of clinical and commercial development.
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development UnderwayVANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform.
